Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott will release its second-quarter 2020 financial results on July 16, 2020, before the market opens. A live webcast of the earnings conference call is scheduled for 8:30 a.m. CT and can be accessed via Abbott's Investor Relations website. This follows the company's commitment to keep stakeholders informed about its financial performance. Abbott operates globally in healthcare, offering solutions across diagnostics, medical devices, nutritionals, and generic medicines, supported by a workforce of 107,000 in over 160 countries.
Abbott announced that its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system has been cleared by the U.S. FDA for adults and children aged 4 and older with diabetes. This system features optional real-time alarms and measures glucose levels every minute, offering a 14-day wear time, the longest for a self-applied iCGM sensor. Its combined mean absolute relative difference (MARD) is 9.3%, ensuring high accuracy. Priced at a third of other CGMs, Abbott aims to make this technology accessible while enhancing diabetes care.
Abbott (NYSE: ABT) announced promising data showing that its FreeStyle Libre system significantly lowers hemoglobin A1c (HbA1c) levels in type 2 diabetes patients, regardless of insulin use. Results from a study presented at the American Diabetes Association (ADA) indicated a drop of 0.8% after six months and 0.6% after one year. Notably, non-insulin users experienced the most significant reductions. Additionally, using the system was linked to a 30% reduction in acute diabetes events and a 13% decrease in hospitalizations, potentially lowering healthcare costs.